PCSK9 and hyperlipidemia: In oncology, Canakinumab increases clearance of drugs metabolized by drug transporter CYP3A422; In cardiology, statins increase clearance of Evolocumab, an anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) mAb in adults with hyperlipidemia, likely via inducing additional PCSK9 expression23.